Kodiak Sciences Inc KOD
Trading Information
- Previous Close Price
- MX$428.00
- Day Range
- MX$749.00–749.00
- 52-Week Range
- MX$51.00–749.00
- Bid/Ask
- MX$1,602.00 / MX$596.00
- Shares Outstanding
- 62.85M
- Market Cap
- $102.91B
- Volume/Avg
- 1 / 1
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 124
- Website
- https://www.kodiak.com
Valuation
|
Metric
|
KOD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 22.89 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KOD
|
|---|---|
Quick Ratio | 2.39 |
Current Ratio | 2.49 |
Interest Coverage | — |
Quick Ratio
KOD
Profitability
|
Metric
|
KOD
|
|---|---|
Return on Assets (Normalized) | −68.71% |
Return on Equity (Normalized) | −224.82% |
Return on Invested Capital (Normalized) | −135.76% |
Return on Assets
KOD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|CD^sng | LOCK|B&q$p | $129B | |||
| Moderna Inc
MRNA
| LOCK|&kJ#!b | LOCK|DMC | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|BFMXr@s | LOCK|%Wv& | $77B | |||
| argenx SE ADR
ARGX
| LOCK|^vhZPG | LOCK|&#w | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<pyM&!K | LOCK|z< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^<shs? | LOCK|@@MSy | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|q#fH#ZDt | LOCK|dy?$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|fK@HT> | LOCK|p? | $24B | |||
| Incyte Corp
INCY
| LOCK|$N%W<$p | LOCK|yX | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$#Fz># | LOCK|Qq | $14B |
United States